Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 430


European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.

Jordan K, Aapro M, Kaasa S, Ripamonti CI, Scotté F, Strasser F, Young A, Bruera E, Herrstedt J, Keefe D, Laird B, Walsh D, Douillard JY, Cervantes A.

Ann Oncol. 2017 Dec 14. doi: 10.1093/annonc/mdx757. [Epub ahead of print]


Continuity and diversity.

Aapro M.

Crit Rev Oncol Hematol. 2018 Jan;121:A2. doi: 10.1016/j.critrevonc.2017.12.001. Epub 2017 Dec 7. No abstract available.


MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.

Gascón P, Krendyukov A, Höbel N, Aapro M.

Eur J Haematol. 2017 Nov 24. doi: 10.1111/ejh.13002. [Epub ahead of print]


Biosimilars in oncology: much ado about nothing?

Aapro M.

Ann Oncol. 2017 Nov 15. doi: 10.1093/annonc/mdx732. [Epub ahead of print] No abstract available.


Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.

Krendyukov A, Schiestl M, Höbel N, Aapro M.

Support Care Cancer. 2018 Jan;26(1):33-40. doi: 10.1007/s00520-017-3861-y. Epub 2017 Sep 20. Review.


Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.

Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L.

Drug Des Devel Ther. 2017 Sep 5;11:2621-2629. doi: 10.2147/DDDT.S133943. eCollection 2017. Review.


Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.


Supportive care for patients undergoing immunotherapy.

Rapoport BL, van Eeden R, Sibaud V, Epstein JB, Klastersky J, Aapro M, Moodley D.

Support Care Cancer. 2017 Jul 13. doi: 10.1007/s00520-017-3802-9. [Epub ahead of print]


Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P.

Eur J Cancer. 2017 Sep;82:193-202. doi: 10.1016/j.ejca.2017.04.014. Epub 2017 Jul 7.


L’accès à l’innovation.

Aapro M, Dietrich PY, Peters S.

Rev Med Suisse. 2017 May 17;13(563):1027. French. No abstract available.


The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M.

Breast. 2017 Jun;33:191-199. doi: 10.1016/j.breast.2017.01.012. Epub 2017 Apr 22.


Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. Review.


The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P, Jordan K, Young A, Aapro M.

Ann Oncol. 2017 Jun 1;28(6):1260-1267. doi: 10.1093/annonc/mdx100.


Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.

Prior JO, Gillessen S, Wirth M, Dale W, Aapro M, Oyen WJG.

Eur J Cancer. 2017 May;77:127-139. doi: 10.1016/j.ejca.2017.01.030. Epub 2017 Apr 7.


3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E.

Ann Oncol. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. No abstract available.


Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.

Barbour S, Smit T, Wang X, Powers D, Arora S, Kansra V, Aapro M, Herrstedt J.

Ann Oncol. 2017 Jun 1;28(6):1268-1273. doi: 10.1093/annonc/mdx073.


Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.

Rugo HS, Rossi G, Rizzi G, Aapro M.

Breast. 2017 Jun;33:76-82. doi: 10.1016/j.breast.2017.02.017. Epub 2017 Mar 10.


Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions.

Vallet-Regí M, Manzano M, Rodriguez-Mañas L, Checa López M, Aapro M, Balducci L.

Oncologist. 2017 Mar;22(3):335-342. doi: 10.1634/theoncologist.2016-0276. Epub 2017 Feb 20. Review.


Geriatric factors and outcomes in metastatic colorectal cancer.

Papamichael D, Aapro M.

Eur J Cancer. 2017 Mar;74:96-97. doi: 10.1016/j.ejca.2016.11.003. Epub 2017 Feb 10. No abstract available.


Supplemental Content

Loading ...
Support Center